KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Research & Development: 2019-2025

Historic Research & Development for Royalty Pharma (RPRX) over the last 7 years, with Sep 2025 value amounting to $50.5 million.

  • Royalty Pharma's Research & Development rose 10000.00% to $50.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $402.0 million, marking a year-over-year increase of 20000.00%. This contributed to the annual value of $2.0 million for FY2024, which is 96.15% down from last year.
  • Royalty Pharma's Research & Development amounted to $50.5 million in Q3 2025, which was down 83.19% from $300.5 million recorded in Q2 2025.
  • Royalty Pharma's 5-year Research & Development high stood at $300.5 million for Q2 2025, and its period low was $500,000 during Q1 2023.
  • Over the past 3 years, Royalty Pharma's median Research & Development value was $500,000 (recorded in 2024), while the average stood at $41.4 million.
  • In the last 5 years, Royalty Pharma's Research & Development crashed by 99.50% in 2023 and then soared by 60,000.00% in 2025.
  • Quarterly analysis of 5 years shows Royalty Pharma's Research & Development stood at $103.8 million in 2021, then tumbled by 51.35% to $50.5 million in 2022, then crashed by 99.01% to $500,000 in 2023, then remained steady at $500,000 in 2024, then skyrocketed by 10,000.00% to $50.5 million in 2025.
  • Its last three reported values are $50.5 million in Q3 2025, $300.5 million for Q2 2025, and $50.5 million during Q1 2025.